Sabrina Lusvarghi, Ph.D.
Affiliations: | 2009 | Carnegie Mellon University, Pittsburgh, PA |
Area:
Organic Chemistry, BiochemistryGoogle:
"Sabrina Lusvarghi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Bruce A. Armitage | grad student | 2009 | Carnegie Mellon | |
| (From molecules to organisms: Molecular recognition using proteins, peptides and peptide nucleic acids.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yang Y, Wu ZX, Wang JQ, et al. (2021) OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology. 12: 620874 |
| Kita DH, Guragossian N, Zattoni IF, et al. (2021) Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. Scientific Reports. 11: 1788 |
| Sajid A, Lusvarghi S, Murakami M, et al. (2020) Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America |
| Ashar YV, Zhou J, Gupta P, et al. (2020) BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers. 12 |
| Wu CP, Hung CY, Lusvarghi S, et al. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology. 114137 |
| Yang Y, Ji N, Teng QX, et al. (2020) Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells . Frontiers in Oncology. 10: 700 |
| Wu CP, Lusvarghi S, Hsiao SH, et al. (2020) Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products |
| Wu CP, Lusvarghi S, Tseng PJ, et al. (2020) MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research. 10: 164-178 |
| Lusvarghi S, Robey RW, Gottesman MM, et al. (2020) Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000research. 9 |
| Wu ZX, Yang Y, Teng QX, et al. (2020) Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 12 |